Current Issue July 2012, Vol. 36, No. 7

Issue Highlights

Comments on Published Paper

Long term follow-up of Polycythemia Vera patients treated with imatinib mesylate
July 2012(Vol. 36 | No. 7 | Pages 815-816)
C. Michael Jones
- Full Text
- PDF (181 KB)

Clinical Studies

Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia
July 2012(Vol. 36 | No. 7 | Pages 817-825)
Adam Gater, Louise Heron, Linda Abetz-Webb, John Coombs, Jeff Simmons, François Guilhot, Delphine Rea

Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course
July 2012(Vol. 36 | No. 7 | Pages 826-831)
Ulrike Bacher, Wolfgang Kern, Tamara Alpermann, Susanne Schnittger, Claudia Haferlach, Torsten Haferlach

First case of ovarian Sertoli-Leydig cell tumor after an allogeneic hematopoietic stem cell transplantation for Hodgkin's disease
25 May 2012
Salvatore Perrone, Irene Pecorella, Walter Barberi, Veronica Valle, Giovanni Fernando Torelli, Fiammetta Natalino, Caterina Mercanti, Robin Foà, Anna Paola Iori
We report on the case of a 16-year-old girl diagnosed in 2001 with Hodgkin's disease (HD), subtype nodular-sclerosing, Ann-Arbor classification Stage II A. She received standard chemotherapy with adri...
Selective toxicity towards myelodysplastic hematopoietic progenitors – Another rationale for iron chelation in MDS
25 May 2012
E. Fibach, E.A. Rachmilewitz
The issue whether iron overload (IO) contributes to the pathophysiology of myelodysplastic syndrome (MDS) and therefore requires treatment, is still controversial. There is no question that patients w...
Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia
25 May 2012
Guilin Tang, Jeffrey L. Jorgensen, Yi Zhou, Ying Hu, Marian Kersh, Guillermo Garcia-Manero, L. Jeffrey Medeiros, Sa A. Wang
Abstract: Bone marrow assessment for myelodysplastic syndrome (MDS) in a patient who develops cytopenia(s) following cancer therapy is challenging. With recent advances in multi-color flow cytometry i...
Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone
24 May 2012
Antonio M. Almeida, Francesca Pierdomenico
To date, azacitidine (Vidaza®, Celgene Corporation, Summit, NJ) is the only agent that has been demonstrated to prolong overall survival versus conventional care regimens (24.5 vs 15.0 months, respect...
Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia
22 May 2012
Hao Xiang Yong, Yeh Ching Linn, Kiat Hoe Ong, Daryl Tan
T-prolymphocytic leukemia (T-PLL) is a rare and aggressive postthymic malignancy with distinctive clinical and morphologic features. The disease is rapidly progressive and is associated with a dismal ...

View More Articles in Press...

Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop
March 2012 (Vol. 36 | No. 3 | Pages 264-270)
Uwe Platzbecker, Valeria Santini, Ghulam J. Mufti, Claudia Haferlach, Jaroslaw P. Maciejewski, Sophie Park, Francesc Solé, Arjan A. van de Loosdrecht, Detlef Haase
The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome
March 2012 (Vol. 36 | No. 3 | Pages 287-292)
I. Cordoba, J.R. Gonzalez-Porras, E. Such, B. Nomdedeu, E. Luño, R. de Paz, F. Carbonell, T. Vallespi, M. Ardanaz, F. Ramos, V. Marco, S. Bonanad, M. Sanchez-Barba, D. Costa, T. Bernal, G.F. Sanz, M.C. Cañizo
Clomiphene as a novel modality for the treatment of acute myeloid leukemia: A pilot phase II study
January 2012 (Vol. 36 | No. 1 | Pages 42-45)
G. Yom-Tov, I. Nathan, O. Shpilberg, A. Polliack, I. Levi
The discovery and early understanding of leukemia
January 2012 (Vol. 36 | No. 1 | Pages 6-13)
Kim R. Kampen
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review
January 2012 (Vol. 36 | No. 1 | Pages 81-86)
Michael J. Rauh, Fazlur Rahman, David Good, Jeffrey Silverman, Michael K. Brennan, Nikolay Dimov, Jane Liesveld, Daniel H. Ryan, W. Richard Burack, John M. Bennett

Most Read lists are compiled every quarter.

On the Cover

New Issue Alert

Free Trial Issue

Journal Ranking

Journal Access

Full-text articles are available from 1995 to the present. Access to abstracts is complimentary. Access to full text is limited to print subscribers. Register or login to:

Buy a Subscription Now

Activate Online Access

Publishing Information

Leukemia Research is published by Elsevier.

Access this journal onSciVerse ScienceDirect

About Leukemia Research

Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and (or) applied clinical research in leukemias, lymphomas, multiple myeloma and other hematologic malignancies. The editors encourage the submission of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell biology, immunology and molecular biology as well as epidemiologic and clinical studies.

Specifically, of major interest will be articles that encompass the application of oncogenes, growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias as well as the myelodysplastic syndromes. In addition we solicit selected articles on the rapidly increasing specialty of marrow or stem cell reconstitution after high dose therapy with curative attempt in patients with a wide range of neoplasms.

MDS Foundation Information

The MDS Foundation is a multidisciplinary, international organization devoted to the prevention, treatment, and study of the myelodysplastic syndromes. The organization is based upon the premise that international cooperation will accelerate the process leading to the control and cure of these diseases.